J3403 HCPCS Level II code: Revakinagene taroretcel-lwey, per implant
J3403 is the HCPCS code for “Revakinagene taroretcel-lwey, per implant” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J3403Revakinagene taroretcel-lwey, per implant
Short description: Revakinagene, per implant
HCPCS · United States
Medicare details
The indicators CMS publishes with J3403 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Oct 1, 2025
Where J3403 sits
- 1J codesDrugs administered other than orally
- 2Active code J3403Revakinagene taroretcel-lwey, per implant
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J3403 mean?
J3403 is the HCPCS code for “Revakinagene taroretcel-lwey, per implant” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J3403?
CMS lists J3403’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J3403
All J codesJ3397Injection, vestronidase alfa-vjbk, 1 mgJ3398Injection, voretigene neparvovec-rzyl, 1 billion vector genomesJ3399Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomesJ3400Injection, triflupromazine hcl, up to 20 mgJ3401Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 mlJ3402Injection, remestemcel-l-rknd, per therapeutic doseJ3404Injection, zopapogene imadenovec-drba suspension, per therapeutic doseJ3405Injection, onasemnogene abeparvovec-brve, per treatmentJ3406Injection, omidubicel-onlv, per therapeutic doseJ3410Injection, hydroxyzine hcl, up to 25 mgJ3411Injection, thiamine hcl, 100 mgJ3415Injection, pyridoxine hcl, 100 mg